All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-infected Patients
The Phase 3 ION-1 Study
- Resource Type
- Conference
- Source
- 한국간담췌외과학회 학술대회지. 2014-04 2014(04):9-9
- Subject
ION-1 NCT01701401 Sofosbuvir Ledipasvir SOF/LDV Phase 3 - Language
- Korean